Sponsored by
This preclinical study helps explain why some cancer cells may be less responsive to Tumor Treating Fields (TTFields). The researchers found that TTFields can activate the PI3K/AKT pathway over time, partly through proteins like FAK and N-cadherin. Importantly, in both cell assays and animal models, blocking the PI3K pathway with inhibitors made cancer cells more sensitive to TTFields.